Nutra Pharma Corporation’s (NPHC) Growth Model T
Post# of 102
Posted On: 01/08/2016 5:43:35 PM
Nutra Pharma Corporation’s (NPHC) Growth Model Thrives in Managing a Multitude of Infectious Diseases
Nutra Pharma Corporation (OTCQB: NPHC) subsidiary Designer Diagnostics focuses its energy on designing and developing medical devices. Established in 2005, the company builds shareholder value by marketing and selling rapid diagnostics test kits for infectious diseases such as tuberculosis (TB) and nontuberculous mycobacteria (NTM).
Designer Diagnostics test kits deliver cost effective and efficient, low infrastructure solutions for identifying and testing the sensitivity of NTM that have the ability to utilize paraffin wax as a sole carbon source or those that are hydrophobic. Designer Diagnostics also delivers an efficient solution for the rapid identification and sensitivity testing of TB.
Designer Diagnostic’s test kits offer many benefits, such as the ability to provide diagnosis in less than seven days. Other attractive characteristics include long shelf life; ability to be stored in extremely hostile environments; cost effectiveness, as compared to most other traditional methods; and they do not require new large capital expenditures, just to name a few.
Recently, Nutra Pharma Corporation released a letter to shareholders. The letter, delivered by Rik J. Deitsch, the company’s chief executive officer, gave investors a brief overview of Nutra Pharma’s progress during 2015, as well as its goals and expectations for the coming months.
“We have had a very busy year at Nutra Pharma,” Deitsch explained in the news release. “2015 has been an inflection year for the company, launching our first new product in over two years (Pet Pain-Away), allowing us to begin to get back into clinical research on our lead drug candidates and bringing our drug platform into focus with the granting of orphan designation for RPI-78M for the treatment of pediatric multiple sclerosis.”
Looked upon as some of the most intriguing news for potential investors was the company’s progress with its therapeutic drug pipeline. In September, the company received orphan status for drug candidate RPI-78M for the treatment of pediatric multiple sclerosis, an indication with no approved treatments currently on the market. Additionally, NPHC continues to make progress toward expanding its retail distribution network for its over-the-counter products. Sales from Nyloxin and Pet Pain-Away are promising revenue streams for the company that are viewed as being vital to the financing of proposed clinical studies.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Nutra Pharma Corporation (OTCQB: NPHC) subsidiary Designer Diagnostics focuses its energy on designing and developing medical devices. Established in 2005, the company builds shareholder value by marketing and selling rapid diagnostics test kits for infectious diseases such as tuberculosis (TB) and nontuberculous mycobacteria (NTM).
Designer Diagnostics test kits deliver cost effective and efficient, low infrastructure solutions for identifying and testing the sensitivity of NTM that have the ability to utilize paraffin wax as a sole carbon source or those that are hydrophobic. Designer Diagnostics also delivers an efficient solution for the rapid identification and sensitivity testing of TB.
Designer Diagnostic’s test kits offer many benefits, such as the ability to provide diagnosis in less than seven days. Other attractive characteristics include long shelf life; ability to be stored in extremely hostile environments; cost effectiveness, as compared to most other traditional methods; and they do not require new large capital expenditures, just to name a few.
Recently, Nutra Pharma Corporation released a letter to shareholders. The letter, delivered by Rik J. Deitsch, the company’s chief executive officer, gave investors a brief overview of Nutra Pharma’s progress during 2015, as well as its goals and expectations for the coming months.
“We have had a very busy year at Nutra Pharma,” Deitsch explained in the news release. “2015 has been an inflection year for the company, launching our first new product in over two years (Pet Pain-Away), allowing us to begin to get back into clinical research on our lead drug candidates and bringing our drug platform into focus with the granting of orphan designation for RPI-78M for the treatment of pediatric multiple sclerosis.”
Looked upon as some of the most intriguing news for potential investors was the company’s progress with its therapeutic drug pipeline. In September, the company received orphan status for drug candidate RPI-78M for the treatment of pediatric multiple sclerosis, an indication with no approved treatments currently on the market. Additionally, NPHC continues to make progress toward expanding its retail distribution network for its over-the-counter products. Sales from Nyloxin and Pet Pain-Away are promising revenue streams for the company that are viewed as being vital to the financing of proposed clinical studies.
For more information on the company, visit www.NutraPharma.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
(0)
(0)